

“The Pink Sheet”[®]

PRESCRIPTION PHARMACEUTICALS AND BIOTECHNOLOGY

F-D-C Reports introduces...

“The Pink Sheet”
DAILY

You like it weekly. You'll love it daily.

Up-to-date pharma/biotech news — at your desk — from your trusted source for over 65 years.

Request your risk-free, 30-day trial now at www.thepinksheetdaily.com

THE NEWS THIS WEEK

Vol. 66, No. 7 February 16, 2004

Erbix Clears FDA; Last Big Approval Of McClellan Era?

- **BRISTOL/IMCLONE EXPECT SECOND ERBITUX MANUFACTURING SITE APPROVAL** in July. Colorectal cancer treatment will be launched with product from Lonza Biologics facility. Approval is first step in Bristol's turnaround strategy **3**
 - **ERBITUX SURVIVAL STUDY TO BE SUBMITTED TO FDA BY EARLY 2007. IMCLONE SAYS** following accelerated approval Feb. 12. Two 1,500-patient studies are expected to complete enrollment in second quarter 2005 and fourth quarter 2006. Erbitux review did not require advisory committee opinion, FDA says, because “the data stood on its own merits” **4**
 - **FDA COMMISSIONER McCLELLAN MAY BE MOVING AGENCIES: CMS SPECULATION** indicates importance of Medicare Rx to Bush Administration. McClellan's background is perfect for CMS, though FDA post is viewed as more attractive **27**
-
- **U.S. annual drug spend will reach \$520 bil. in 2013, CMS projects**, close to triple the expenditure in 2003 **29**
 - **Pfizer relies on “healthy competition” among research teams** to preserve entrepreneurial spirit of discovery scientists. Company recognizes “dark side” to scale, tries to preserve spirit of loyalty to “the project.” Pfizer does not plan sales force cuts, despite what it sees as “invitation” to do so from competitors **13**
 - **GSK not interested in making “White Knight” bid for Aventis**; company remains confident that internal R&D efforts will generate future growth. GSK faces “transition” year in 2004 **7**
 - **Aventis/Genta oncologic Genasense is expected to receive advisory committee review** in early May **6**
 - **Hormone therapy “black box” class warning on dementia risk requested by FDA** labeling for Wyeth's *Prempro/Premarin* already includes a dementia warning, but not a “black box” **19**
 - **Wyeth *Prevnar* allocation plan extended** to July; providers will receive 80% of average **20**
 - **“Shared exclusivity” could apply to eight first-time generics** over next two years, FDA **23**
 - **Dr. Reddy's *AmVaz* approval stayed; FDA re-evaluating source of data** supporting competitor's *Norvasc* **24**
 - **PhRMA close to deal with Rep. Tauzin; communications, reg affairs changes** reflect scope of transition process **25**
 - **Merck will give drugs free to Medicare “debit” card qualifiers** after their \$600 transitional assistance grant is used up. Merck/Schering-Plough's *Zetia* in not included in the offer **33**
 - **Medco's cash reserves will give the company flexibility in its approach to the Medicare Rx benefit**, firm says **33**
 - **Rx supply chain should be on “code red” for possible counterfeits ahead of April 1** implementation date for paper pedigrees, specialty distributor maintains. Dubious products may flood market before pedigree requirement kicks in.... **36**

Univ. of Minn.
Bio-Medical
Library

Contents copyrighted © F-D-C Reports, Inc. 2004; protected by U.S. Copyright Law. Reproduction, photocopying, storage or transmission by magnetic or electronic means strictly prohibited by law. Authorization to photocopy items for internal or personal use is granted by F-D-C Reports, Inc., when the fee of \$7.50 per copy of each page is paid directly to Copyright Clearance Center, 222 Rosewood Dr., Danvers, MA 01923, (978) 750-8400. The Transaction Reporting Service fee code is: 1530-6240/04 \$0.00 + \$7.50. Violation of copyright will result in legal action, including civil and/or criminal penalties, and suspension of service. For more information contact: Michael Manouliak, F-D-C Reports, Inc. at

Bayer/PPD Implitapide Development Follows Zetia Model As Statin Add-On

PPD will adopt Merck/Schering-Plough's *Zetia* model in developing Bayer's implitapide as an add-on therapy in the lipid-lowering market, PPD subsidiary MRL International CEO Evan Stein, MD/PhD, said.

"We're not looking to compete with the statin market." While "no new agent is going to replace statin therapy...we've seen ezetimibe, Zetia, come onto the market and obtain a significant market share," Stein said during PPD's investor day Feb. 5.

PPD is conducting *Phase II* proof-of-concept studies on the use of implitapide (BAY-13-9952) as an add-on to statin therapy. The contract research organization licensed the microsomal triglyceride transfer protein inhibitor from Bayer.

PPD is hoping to demonstrate implitapide's safety and efficacy in homozygous and severe heterozygous familial hypercholesterolemia "where even high-dose statins are ineffective or inadequate," Stein said. The drug is also being studied for hypertriglyceridemia.

The studies, which will enroll approximately 200 patients, are expected to position the drug as a way to improve upon statin therapy, much in the same way that Zetia is marketed, Stein said.

"The addition here of another 18% to 24% [LDL reduction] would allow us to build on current therapy," he said. Zetia's success "provides an equal opportunity for other drugs that can produce 18% to 24% LDL reduction safely in a single-dose pill on top of all existing therapy."

When used as an add-on to a statin, Zetia has a statistically significant effect on reducing LDL cholesterol. For example, across all *Lipitor* (atorvastatin) doses the combination reduces LDL levels 56% versus 44% with the statin alone.

Some analysts have questioned the pace of Zetia's uptake, however; new and total prescription share in December was 5.2% and 4.9%, after a little over a year on the market ("The Pink Sheet" Feb. 2, 2004, p. 11).

Patients initially targeted for implitapide therapy will likely be the 5%-7% of high cholesterol patients that are statin-intolerant and the 10% -15% who are at high risk for cardiovascular disease and have not reached their LDL goals. Stein indicated

Zetia is similarly targeted. By contrast, Merck expects the *Zetia/Zocor* fixed-dose combination pending at FDA to compete directly with single-agent statins for patients who are diagnosed with high cholesterol but not treated ("The Pink Sheet" Dec. 22, 2003, p. 23).

PPD suggested implitapide could eventually be used as a triple combination therapy with Zetia and a statin. In that case, Stein estimated that LDL-cholesterol reductions could range between 66%-72%.

Implitapide could mark Bayer's return to the lipid-lowering market after the 2001 Baycol withdrawal.

PPD expects Bayer will be interested in buying back rights to implitapide after seeing the *Phase II* results. "If they meet, I think, even a reasonable hurdle, Bayer will be pretty keen to take it," Stein maintained.

Bayer will have the opportunity to relicense implitapide from PPD by reimbursing *Phase II* costs and establishing milestone and royalty payments.

"One of the things that may drive them is if they don't take it, they know a number of other major pharma would probably. They are speaking to us and are interested in the results," Stein said.

Implitapide would mark Bayer's return to the lipid-lowering market; the company withdrew the statin *Baycol* (cerivastatin) in 2001 due to reports of rhabdomyolysis, including deaths ("The Pink Sheet" Aug. 13, 2001, p. 4).

While Stein acknowledged that MTP inhibitor projects have been pursued by a number of companies, including Bristol-Myers Squibb, Johnson & Johnson and Pfizer, he argued that the toxicity seen with some of those projects was related to the high doses used during trials

"None of them were looking at LDL reductions or cholesterol reductions" as low as the 20% range, he said. "They didn't consider that viable in terms of marketing. There was no Zetia on the market, so there was no model for them."

PPD is conducting three 39-week *Phase II* studies with dose titration occurring every five weeks based on safety and tolerability examined at four weeks. The starting dose will be 10 mg daily, escalating by 5 mg/day every five weeks to a maximum 40 mg/day. ♦ ♦